复星医药：控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份并于香港联交所上市流通的申请事项，已完成中国证监会备案

国际金融报01-16

复星医药公告，控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份(即H股)并于香港联交所上市流通的申请事项，已完成中国证监会备案。其中，本公司控股子公司复星新药持有的1.2亿股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股1.52亿股、非上市股1.92亿股。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603969492?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-16 17:05","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2603969492","market":"hk","top_or_hot":-1,"title":"复星医药：控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份并于香港联交所上市流通的申请事项，已完成中国证监会备案","media":"国际金融报","content":"<div>\n<p>复星医药公告，控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份(即H股)并于香港联交所上市流通的申请事项，已完成中国证监会备案。其中，本公司控股子公司复星新药持有的1.2亿股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股1.52亿股、非上市股1.92亿股。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药：控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份并于香港联交所上市流通的申请事项，已完成中国证监会备案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药：控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份并于香港联交所上市流通的申请事项，已完成中国证监会备案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 17:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b><strong>国际金融报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药公告，控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份(即H股)并于香港联交所上市流通的申请事项，已完成中国证监会备案。其中，本公司控股子公司复星新药持有的1.2亿股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股1.52亿股、非上市股1.92亿股。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b","article_id":"2603969492","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603969492","pubTimestamp":1768554310,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"复星医药公告，控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份(即H股)并于香港联交所上市流通的申请事项，已完成中国证监会备案。其中，本公司控股子公司复星新药持有的1.2亿股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股1.52亿股、非上市股1.92亿股。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","BK1593":"医美概念股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","02696":"复宏汉霖","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","02196":"复星医药","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC"},"translate_title":"Fosun Pharma: The application for converting 183 million domestic unlisted shares of Henlius held by several shareholders of its holding subsidiary Henlius into overseas listed shares and listing and circulation on the Hong Kong Stock Exchange has been completed. China Securities Regulatory Commission filing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5,"02196":1.5},"content_text":"复星医药公告，控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份(即H股)并于香港联交所上市流通的申请事项，已完成中国证监会备案。其中，本公司控股子公司复星新药持有的1.2亿股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股1.52亿股、非上市股1.92亿股。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603969492","isCrawlerRequest":true}